by Benefits Alliance | Mar 18, 2019 | Government Benefits, Group Benefits, Human Resources, Prescription Drugs
The Ontario government is making changes to its OHIP+ Children and Youth Pharmacare program, as you know. The changes affect Ontario residents aged 24 and under, as follows: Those with prescription drug coverage under a private plan will access prescribed...
by Benefits Alliance | Jan 30, 2019 | Group Benefits, Health and Wellness, Prescription Drugs
Check out what our specialists have to say in our recent white paper titled, “Group Benefits Roundtable”. Topics of discussion include Bio-Similars, Managing Diabetes, Adult Vaccinations and dealing with Chronic Pain. Click below for the published article....
by Benefits Alliance | Aug 23, 2018 | Business Owners, Group Benefits, Health and Wellness, Human Resources, Prescription Drugs
Only one-third of Canadian employers feel prepared for the impending legalization of cannabis, according to a new survey produced by Mercer Canada. A total of 366 Canadian employers and more than 1,000 employees, found another third feels somewhat prepared and 27 per...
by Benefits Alliance | Jul 4, 2018 | Government Benefits, Group Benefits, Prescription Drugs
One of the first things on the Ontario Progressive Conservative agenda was to change OHIP+. Fundamentally the program will be the same, including who is covered and what is covered; however the government will now be 2nd payor instead of 1st payor. Individuals who...
by Benefits Alliance | Apr 23, 2018 | Business Owners, Government Benefits, Group Benefits, Prescription Drugs
Recent article published by the Benefits & Pension Monitor National pharmacare is no longer an if, but a when, says Chris Bonnett, principal consultant with H3 Consulting. Speaking at The Benefits Alliance Group 2018 AGM and Spring Conference ‘Climbing Higher,’ he...
by Benefits Alliance | Mar 19, 2018 | Business Owners, Government Benefits, Group Benefits, Prescription Drugs, Reports
In December 2017 the Canadian Leadership Council on Drug Plan Partnerships met to discuss how Private and Pharmacare can partner to share in the risks of a National Drug Program. Included in this meeting were our own Paul Crossdale, President MC&A and Kathleen...
